Hikma appoints Dr. Hafrun Fridriksdottir as President of Generics business

Press Release Corporate 15 April 2024

Hikma appoints Dr. Hafrun Fridriksdottir as President of Generics business

London, 15 April 2024 – Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announces that Dr. Hafrun Fridriksdottir has been appointed President of its Generics business, effective today. Hafrun will report to Riad Mishlawi, Hikma’s Chief Executive Officer, and joins the senior management team as a member of Hikma’s Executive Committee.  She will be based in the company’s Berkeley Heights, New Jersey offices. Hafrun succeeds Brian Hoffmann, who will leave Hikma effective May 1st.

Hafrun brings more than 25 years of pharmaceutical industry experience to her new role.  During her career, Hafrun has held senior executive and research and development positions at leading global pharmaceutical companies including Alvotech, Teva Pharmaceuticals, Allergan and Actavis, and most recently has served in advisory and board roles for several biotech and mid-sized pharma companies.

“I am pleased to appoint Hafrun to this vital role,” said Riad.  “Hafrun's vast experience in leading high performing research and development teams brings new capabilities needed for driving Hikma’s Generics business in its next phase of growth. She will be especially helpful in further expanding Hikma’s product portfolio and its position as a market-leading domestic US manufacturer and supplier of generic medicines.  On behalf of Hikma’s Board of Directors and our executive management team, I want to thank Brian for his many contributions to Hikma during his 15 years with the company.”

Hafrun added: "This is a very exciting opportunity for me to lead a highly talented team, who have been growing and developing this business over many years. I am confident that together we will strengthen our R&D pipeline, leverage our strong manufacturing capabilities and establish new business opportunities that will further build our position as one of the top providers of generic medicines in the US.”